TYK2 inhibitor for adults with moderate to severe plaque psoriasis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional trial compares a TYK2 inhibitor against placebo in adults with moderate to severe plaque psoriasis treated for 12 weeks. Eligible participants are adults aged 18–70 with at least six months of plaque psoriasis and specific weight and BMI requirements. Participants will receive either the TYK2 inhibitor or placebo and will be monitored for changes in skin disease severity and for side effects. The protocol excludes people with non-plaque psoriasis, prior TYK2 inhibitor use, recent systemic or biologic psoriasis treatments, or certain chronic or severe infections.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male and female, ages 18 to 70 years
* Body weight \>40 kg, body mass index (BMI) of 18 to 40 kg/m2
* Clinical diagnosis of plaque psoriasis for ≥6 months before the Baseline visit
* Women of childbearing potential (WOCBP) and males who are sexucally active must agree to follow instructions for method(s) of contraception.

Exclusion Criteria:

* Diagnosed with non-plaque psoriasis
* Previously received tyrosine kinase 2 (TYK2) inhibitors
* Previously received other psoriasis treatments such as biological agents, immunoregulators, or hormonal drugs within a specific period before administration, and the investigator deems it may affect the immunity of the subjects
* Has participated in any clinical trials within 30 days or 5 half-lives of the drug before the first administration, or currently undergoing visits for other clinical trials;
* Has history of chronic disease that may affect the study, or acute or chronic severe infectious diseases, such as a history of active or inadequately treated latent tuberculosis infection, severe bone or joint infections within 6 months before screening, and other acute infectious diseases.
* Has known or suspected skin or systemic autoimmune diseases other than psoriasis and psoriatic arthritis;
* Other conditions that the investigator deems unsuitable for participation in this study.

Other protocol defined inclusion/exclusion criteria could apply

Where it's running

• Shanghai Skin Disease Hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Yang Zhang
• Email: yang_zhang@usynova.com
• Phone: +8613636393195

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HS-20137: a treatment option for adults with moderate-to-severe plaque psoriasis

  A phase 2 open-label study tests HS-20137 given as 200 mg at weeks 0, 4 and 8 to see if it is safe and helps patients with moderate-to-severe plaque psoriasis.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Beijing, Beijng · NCT07879885

• How safe and well ZP9830 works in people with plaque psoriasis over 8 weeks

  This study tests whether ZP9830 is safe and tolerable in adults with plaque psoriasis for 8 weeks, with a comparison to placebo.

  Recruiting Phase 1 Zealand Pharma · Leiden, South Holland · NCT07733089

• Secukinumab retention in adults with plaque psoriasis and MASLD in Spain

  This study tests how long people with plaque psoriasis and MASLD stay on secukinumab in real-world Spain, using EMR data from several hospitals.

  Recruiting at 9 sites Novartis · Badalona, Barcelona and 8 other locations · NCT07683065

• WD-890 in adults with moderate to severe plaque psoriasis

  This study tests whether WD-890 tablets work better than a placebo for adults with moderate to severe plaque psoriasis.

  Recruiting Phase 3 Zhejiang Wenda Pharma Technology LTD. · Nanjing, Jiangsu · NCT07672561

• Long-term ORKA-001 treatment for adults with plaque psoriasis

  This open-label extension will try ORKA-001 long-term in adults with moderate-to-severe plaque psoriasis who completed a previous ORKA-001 study.

  Recruiting at 39 sites Phase 2 Oruka Therapeutics, Inc. · Phoenix, Arizona and 38 other locations · NCT07449702

• D-2570 oral treatment for adults with moderate to severe plaque psoriasis

  This trial tests whether the oral medicine D-2570 helps adults with moderate to severe plaque psoriasis compared with placebo and an approved oral drug.

  Recruiting Phase 3 InventisBio Co., Ltd · Shanghai, Shanghai Municipality · NCT07326813

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.